Prediction of Phenotypic Severity in Mucopolysaccharidosis Type IIIA

Overview

Journal Ann Neurol

Specialty Neurology

Date 2017 Oct 13

PMID 29023963

Citations 8

Authors

Suzan J G Knottnerus

Stephanie C M Nijmeijer

Lodewijk Ijlst

Heleen Te Brinke

Naomi van Vlies

Frits A Wijburg

Affiliations

Soon will be listed here.

Abstract

Objective: Mucopolysaccharidosis IIIA or Sanfilippo disease type A is a progressive neurodegenerative disorder presenting in early childhood, caused by an inherited deficiency of the lysosomal hydrolase sulfamidase. New missense mutations, for which genotype-phenotype correlations are currently unknown, are frequently reported, hampering early prediction of phenotypic severity and efficacy assessment of new disease-modifying treatments. We aimed to design a method to determine phenotypic severity early in the disease course.

Methods: Fifty-three patients were included for whom skin fibroblasts and data on disease course and mutation analysis were available. Patients were phenotypically characterized on clinical data as rapidly progressing or slowly progressing. Sulfamidase activity was measured in fibroblasts cultured at 37 °C and at 30 °C.

Results: Sulfamidase activity in fibroblasts from patients homozygous or compound heterozygous for a combination of known severe mutations remained below the limit of quantification under both culture conditions. In contrast, sulfamidase activity in fibroblasts from patients homozygous or compound heterozygous for a known mild mutation increased above the limit of quantification when cultured at 30 °C. With division on the basis of the patients' phenotype, fibroblasts from slowly progressing patients could be separated from rapidly progressing patients by increase in sulfamidase activity when cultured at 30 °C (p < 0.001, sensitivity = 96%, specificity = 93%).

Interpretation: Phenotypic severity strongly correlates with the potential to increase sulfamidase activity in fibroblasts cultured at 30 °C, allowing reliable distinction between patients with rapidly progressing or slowly progressing phenotypes. This method may provide an essential tool for assessment of treatment effects and for health care and life planning decisions. Ann Neurol 2017;82:686-696.

Citing Articles

Mucopolysaccharidoses types I and IIIA: Diagnosis and identification of novel polymorphisms associated with common mutations in Moroccan patients.

El Fissi H, Bouzid F, Sebbar M, Serghini M, Msanda F, Alif N Mol Genet Metab Rep. 2025; 42:101186.

PMID: 39897474 PMC: 11787024. DOI: 10.1016/j.ymgmr.2025.101186.

An Engineered Mutant Zebrafish Recapitulates Molecular and Behavioural Pathobiology of Sanfilippo Syndrome A/MPS IIIA.

Douek A, Khabooshan M, Henry J, Stamatis S, Kreuder F, Ramm G Int J Mol Sci. 2021; 22(11).

PMID: 34073041 PMC: 8197930. DOI: 10.3390/ijms22115948.

Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses.

Rintz E, Gaffke L, Podlacha M, Brokowska J, Cyske Z, Wegrzyn G Int J Mol Sci. 2020; 21(9).

PMID: 32366041 PMC: 7246638. DOI: 10.3390/ijms21093194.

Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease.

Heon-Roberts R, Nguyen A, Pshezhetsky A J Clin Med. 2020; 9(2).

PMID: 32012694 PMC: 7074161. DOI: 10.3390/jcm9020344.

Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.

Losada Diaz J, Cepeda Del Castillo J, Rodriguez-Lopez E, Almeciga-Diaz C Int J Mol Sci. 2020; 21(1).

PMID: 31905715 PMC: 6981736. DOI: 10.3390/ijms21010232.

References

Sidhu N, Schreiber K, Propper K, Becker S, Uson I, Sheldrick G . Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA. Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 5):1321-35. PMC: 4014121. DOI: 10.1107/S1399004714002739. View

Fuller M, Tucker J, Lang D, Dean C, Fietz M, Meikle P . Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet. 2011; 48(6):422-5. DOI: 10.1136/jmg.2010.088096. View

Meijer O, Welling L, Valstar M, Hoefsloot L, Bruggenwirth H, van der Ploeg A . Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB. J Inherit Metab Dis. 2016; 39(3):437-445. PMC: 4851702. DOI: 10.1007/s10545-016-9916-2. View

Houten S, Frenkel J, Rijkers G, Wanders R, Kuis W, Waterham H . Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet. 2002; 11(25):3115-24. DOI: 10.1093/hmg/11.25.3115. View

Yogalingam G, Hopwood J . Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Hum Mutat. 2001; 18(4):264-81. DOI: 10.1002/humu.1189. View

Scott H, Blanch L, Guo X, Freeman C, Orsborn A, Baker E . Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet. 1995; 11(4):465-7. DOI: 10.1038/ng1295-465. View

Smith P, Krohn R, Hermanson G, Mallia A, Gartner F, Provenzano M . Measurement of protein using bicinchoninic acid. Anal Biochem. 1985; 150(1):76-85. DOI: 10.1016/0003-2697(85)90442-7. View

Schueler U, Kolter T, Kaneski C, Zirzow G, Sandhoff K, Brady R . Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis. 2005; 27(5):649-58. DOI: 10.1023/b:boli.0000042959.44318.7c. View

Leinekugel P, Michel S, Conzelmann E, Sandhoff K . Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet. 1992; 88(5):513-23. DOI: 10.1007/BF00219337. View

10.

Kingma S, Wagemans T, Ijlst L, Bronckers A, van Kuppevelt T, Everts V . Altered interaction and distribution of glycosaminoglycans and growth factors in mucopolysaccharidosis type I bone disease. Bone. 2016; 88:92-100. DOI: 10.1016/j.bone.2016.01.029. View

11.

Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C . Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther. 2014; 25(6):506-16. DOI: 10.1089/hum.2013.238. View

12.

Poorthuis B, Wevers R, Kleijer W, Groener J, De Jong J, Van Weely S . The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999; 105(1-2):151-6. DOI: 10.1007/s004399900075. View

13.

Pollard L, Jones J, Wood T . Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations. J Inherit Metab Dis. 2012; 36(2):179-87. DOI: 10.1007/s10545-012-9533-7. View

14.

Muenzer J . Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2012; 50 Suppl 5:v4-12. DOI: 10.1093/rheumatology/ker394. View

15.

Jones S, Breen C, Heap F, Rust S, de Ruijter J, Tump E . A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab. 2016; 118(3):198-205. DOI: 10.1016/j.ymgme.2016.05.006. View

16.

Muschol N, Storch S, Ballhausen D, Beesley C, Westermann J, Gal A . Transport, enzymatic activity, and stability of mutant sulfamidase (SGSH) identified in patients with mucopolysaccharidosis type III A. Hum Mutat. 2004; 23(6):559-66. DOI: 10.1002/humu.20037. View

17.

Valstar M, Ruijter G, van Diggelen O, Poorthuis B, Wijburg F . Sanfilippo syndrome: a mini-review. J Inherit Metab Dis. 2008; 31(2):240-52. DOI: 10.1007/s10545-008-0838-5. View

18.

Heron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C . Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A. 2011; 155A(1):58-68. DOI: 10.1002/ajmg.a.33779. View

19.

Buhrman D, Thakkar K, Poe M, Escolar M . Natural history of Sanfilippo syndrome type A. J Inherit Metab Dis. 2013; 37(3):431-7. DOI: 10.1007/s10545-013-9661-8. View

20.

Gabrielli O, Coppa G, Bruni S, Villani G, Pontarelli G, Di Natale P . An adult Sanfilippo type A patient with homozygous mutation R206P in the sulfamidase gene. Am J Med Genet A. 2005; 133A(1):85-9. DOI: 10.1002/ajmg.a.30552. View